Click it and Unblock the Notifications
For Daily Alerts
Just In
Don't Miss
-
0.50% Dividend Yield: Midcap Cement Stock Slumps 10% Following Weak Q4 Results; Profit Down 48% YoY -
Accelerating HealthTech Innovation: Apply Now for BFI-BIOME Fellowships at Venture Center -
When will India squad for T20 World Cup 2024 be announced? What is ICC's official deadline date? -
From Alia Bhatt To Kriti Sanon, Korean Beauty Products That Bollywood Divas Swear By -
OnePlus Watch 2 New Nordic Blue Colour Option Launched; Here’s How Much It Costs -
2024 Jeep Wrangler Facelift Launched In India - Prices Start At Rs 67.65 Lakhs -
Supriya Menon’s Heartfelt Anniversary Post For Husband Prithviraj Sukumaran: 13 Years With You! Wow! -
Escape to Kalimpong, Gangtok, and Darjeeling with IRCTC's Tour Package; Check Itinerary
Strides Arcolab receives 2nd injectable ANDA approval for Tobramyc
New Delhi, Mar 12 (UNI) Strides Arcolab Ltd today announced its second Abbreviated New Drug Application (ANDA) approval for Tobramycin 40 mg/mL.
The product is licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn, Inc and Strides Arcolab Ltd.
Tobromycin is the second approval amongst 22 sterile submissions the company has submitted with US FDA.
UNI
BJR
PBB
RN1458
Story first published: Wednesday, March 12, 2008, 17:17 [IST]
